Evaluation of Herbal Extracts for the Treatment of Anxiety and Depression: A Comprehensive Review

Somrik Panja, Kunal Dutta, Debabrata Das, Souvik Bag, Peojit Khan, Prahlad Kumar Sarkar,

doi:10.5281/zenodo.15569919

Review Paper | Open Access
Volume 03 | Issue 06 | Article Id IJPS/250305507

Evaluation of Herbal Extracts for the Treatment of Anxiety and Depression: A Comprehensive Review
Somrik Panja* Kunal Dutta Debabrata Das Souvik Bag Peojit Khan Prahlad Kumar Sarkar
Department of Pharmacy, Bengal College of Pharmaceutical Technology, Dubrajpur-731123, West Bengal, India.

Abstract

Anxiety and depression are two of the most prevalent mental illnesses in the world, impacting millions of individuals each year. Although they have been used extensively, traditional pharmacological treatments like benzodiazepines and selective serotonin reuptake inhibitors (SSRIs) have been linked to withdrawal symptoms, dependence, and negative side effects over time. Particularly since they are seen as safe and effective, this has brought fast interest in different methods such as herbal medicine. Preclinical research shows several herbal extracts, including Erythrina sp., Clitoria ternatea, and several essential oils, to have hopeful anxiolytic and antidepressant qualities. Including modulation of the monoaminergic system, interaction with gamma aminobutyric acid (GABA) receptors, and decrease of neuroinflammation and oxidative stress, these plant-based molecules act on many fronts. The preclinical support for the use of these herbal extracts for anxiety and depression is thoroughly reviewed in this article, their mechanisms of action debated, and the difficulties to be solved for their clinical translation emphasized.

Keywords

selective serotonin reuptake inhibitors (SSRIs), Erythrina sp., Clitoria ternatea, oxidative stress, neuroinflammation

Introduction

Anxiety and depression are major global health issues that greatly help to cause economic burden and disability⁴. While proven to be effective, conventional drug therapy—including selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), and benzodiazepines^74,75 —is sometimes linked with side effects as sedation, stomach difficulties, and dependence⁵. These disadvantages have given way to alternative medicine, especially herbal medicines. In managing anxiety and depression, traditional medical systems such Ayurveda, Traditional Chinese Medicine (TCM), and Kampo^76,77 have used herbal extracts⁶. Through several biological routes, early laboratory work shows that some herbal extracts have anxiolytic and antidepressant qualities for example, Erythrina sp., While Clitoria ternatea⁷³ is known for its neuroprotective properties via serotonergic modulation, compounds in rooibos tea⁷⁸ have been discovered to have anxiolytic effects via GABAergic neurotransmission modification⁷. More and more studies on herbal applications point to their alternative or complementary value in fighting depression and anxiety, calling for additional inquiry by scientific means.

<a href="https://www.ijpsjournal.com/uploads/createUrl/createUrl-20250601193812-6.png" target="_blank">
<img alt="1.png" height="150" src="https://www.ijpsjournal.com/uploads/createUrl/createUrl-20250601193812-6.png" width="150">
</a>
Figure 1: Color model of basic emotions. (A). Newton’s prismatic colors diagram, and Newton states that there are seven primary colors. (B). The image displays Ekman’s seven basic emotions (fear, anger, joy, surprise, contempt, sadness, and disguZ`st). (C). The image displays our hypothesis of three primary emotions: joy, disgust (sadness), and fear (anger), which are associated with three monoamine neurotransmitters.²⁵

2. Mechanisms of Action of Herbal Extracts

Herbal extracts exert their therapeutic effects on anxiety and depression through multiple pharmacological mechanisms ^8,79. These include:
2.1. Monoaminergic Modulation: Many herbal extracts increase the levels of key neurotransmitters such as serotonin (5-HT), norepinephrine (NE), and dopamine (DA), which are crucial for mood regulation ⁹. Hypericum perforatum (St. John’s Wort), for example, inhibits serotonin reuptake, mimicking the action of SSRIs ¹⁰.

2.1.1. Monoamine Neurotransmitter & Other Neurotransmitters:

In the field of emotions, psychological analyses have advanced remarkably and these pathbreaking studies have aided in the discovery of many key structures related to primary emotions. Still, monoamine neurotransmitters have a broad projection that could impact the function of the whole brain and even the whole body ²⁶. Therefore, monoamine neurotransmitters are also referred to as neuromodulators, such as dopamine, norepinephrine, and serotonin (DA, NE, and 5-HT). These monoamine neuromodulators may be the main neural substrates for emotions, and we proposed that emotions are nothing but neuromodulators ^27,28,29. Monoamine neuromodulators serve as the main neural foundation for emotions; however, numerous other substances in the brain also play a role in emotions, including corticotropin-releasing hormone (CRH), cortisone, oxytocin, and sex hormones. The interactions between all these neurotransmitters and their effects on various processes can vary from one patient to another. This variability may lead to several chemical imbalances, resulting in diversity among patients with Major Depressive Disorder (MDD). While monoamine neuromodulators may be the key neural basis of emotions, other related chemicals like hormones, inflammatory cytokines, neurotrophic factors, and mRNA or LnRNA could function as important biomarkers for MDD²⁵.
<a href="https://www.ijpsjournal.com/uploads/createUrl/createUrl-20250601193812-5.png" target="_blank">
<img alt="2.png" height="150" src="https://www.ijpsjournal.com/uploads/createUrl/createUrl-20250601193812-5.png" width="150">
</a>
Figure 2: Monoamine neurotransmitters regulate primary emotions and crucially impact major depressive disorders.

2.2. GABAergic and Glutamatergic Pathways: Some herbal compounds raise GABAergic activity, hence reducing anxiety ¹¹. Erythrina family members. Extracts, for instance, have been demonstrated to bind GABAA receptors, alike benzodiazepines, but free from the addiction possibilities ¹².

2.2.1. Biosynthesis of GABA: GABA is synthesized from its precursor glutamate in the cytoplasm of presynaptic neurons. The reaction is catalyzed by glutamate decarboxylase (GAD) & a vitamin B6 (pyridoxine) cofactor-requiring enzyme. GABA is then loaded into synaptic vesicles by the vesicular inhibitory amino acid transporter. When it reaches the presynaptic terminal in an action potential, GABA is released into the synaptic cleft, where it might bind to GABA receptors on the postsynaptic neuron. GABA is then degraded by GABA-transaminase to succinate semialdehyde, which is recycled into the citric acid cycle ^30,44.

<a href="https://www.ijpsjournal.com/uploads/createUrl/createUrl-20250601193812-4.png" target="_blank">
<img alt="3.png" height="150" src="https://www.ijpsjournal.com/uploads/createUrl/createUrl-20250601193812-4.png" width="150">
</a>
Figure 3: GABA Synthesis

2.2.2. GABA Receptors: GABA produces its effects by binding to two main types of receptors:

GABA-A Receptors: These are ionotropic receptors that constitute chloride ion channels, which result in hyperpolarization of the neuron and suppression of action potentials. Some of the subunits of GABA-A receptors, for instance, α2 and α3, have been found to be modulated with anxiolytic action without the sedative action one would usually get with non-selective benzodiazepines ^31,45,46.
GABA-B Receptors: They are metabotropic G-protein-linked receptors, which influence neuronal function by second messenger systems. Preclinical and clinical trials suggest that GABA-B receptors are potential targets for therapeutic intervention in anxiety and mood disorders. This has been limited by agonist side effects. The discovery of positive allosteric modulators offers a potential therapeutic intervention ^32,45,46.

<a href="https://www.ijpsjournal.com/uploads/createUrl/createUrl-20250601193812-3.png" target="_blank">
<img alt="4.png" height="150" src="https://www.ijpsjournal.com/uploads/createUrl/createUrl-20250601193812-3.png" width="150">
</a>
Figure 4: Structure of the GABA receptor and position of the binding sites for different drugs.

2.2.3. Neuroanatomic role of GABAergic & Glutamatergic pathways in anxiety & Depression:

Gamma-aminobutyric acid (GABA) and glutamate are the major neurotransmitters in the central nervous system, elaborately involved in modulating anxiety through their respective inhibitory and excitatory pathways ⁴⁹.

GABAergic Pathways: GABAergic neurological transmission plays a major role in regulating anxiety responses, particularly within the amygdala which is a major brain region involved in emotional processing. The amygdala consists of various nuclei, with the basolateral amygdala (BLA) and the central nucleus of the amygdala (CeA) which also being particularly important. The BLA receives sensory input and, via excitatory glutamatergic projections, stimulates the CeA. Between these nuclei are GABAergic interneurons referred to as intercalated cells that control the excitatory information from the BLA to the CeA, thus affecting responses to anxiety. Administration of GABA or GABA receptor agonists to the amygdala has been found to reduce fear and anxiety measures, while GABA antagonists cause anxiogenic effects^33,47,48.

<a href="https://www.ijpsjournal.com/uploads/createUrl/createUrl-20250601193812-2.png" target="_blank">
<img alt="5.png" height="150" src="https://www.ijpsjournal.com/uploads/createUrl/createUrl-20250601193812-2.png" width="150">
</a>
Figure 5: Neurological circuits behind anxiety disorders.

Notes: Main outputs of the CeA and BNST: - blue arrows; main outputs of the BLA: - orange arrows; main inputs to the BLA: - green arrows.
Abbreviations: BLA (basolateral amygdala); BNST (bed nucleus of the stria terminalis); CeA (central nucleus of the amygdala); PFC (prefrontal cortex); ACC (anterior cingulate cortex) GABAergic neurotransmission also helps to control anxiety & depression along with the amygdala in regions like the prefrontal cortex (PFC) and hippocampus. Top down regulatory control of the amygdala is provided by the prefrontal cortex, with GABAergic interneurons within the PFC playing a part in this modulation. Changes in GABAergic activity in would be linked with anxiety disorders within these areas ³⁴.

Glutamatergic Pathways: Glutamate, the major excitatory neurotransmitter, is central to the neural networks that control anxiety. Within the amygdala, glutamatergic neurons of the BLA send projections to the CeA to allow the expression of anxiety responses. The PFC provides excitatory glutamatergic projections to the amygdala, modulating its activity and, in turn, anxiety. Dysregulation of glutamatergic neurotransmission within these circuits has been involved in the pathophysiology of anxiety disorders ^33,47,50,51. In summary, regulation of anxiety largely depends on the balance between GABAergic inhibitory and glutamatergic excitatory signals within brain circuits, particularly those associated with the amygdala and prefrontal cortex. When these two are unstable, elevated levels of anxiety are likely, indicating the major role that plays these neurotransmitter systems in modulating anxiety.

2.3. Anti-inflammatory and Antioxidant Properties: Mood disorders have mostly been regulated by two major pathophysiologic factors such as neuroinflammation and oxidative stress, so anti-inflammatory and antioxidant qualities offer help ¹³. Plant extracts such as Curcuma longa and Withania somnifera show anti-inflammatory properties through cytokine suppression including interleukin6 (IL-6) and tumor necrosis factor alpha (TNFα) ¹⁴. Ashwagandha root extract (ARE) lower the levels of inflammation related proteins including cyclooxygenase2 (COX2), inducible nitric oxide synthase (iNOS), interleukin6 (IL-6), interleukin1β (IL1β), and tumor necrosis factor alpha (TNFα). Normally elevate because to chronic stress and neuroinflammatory disorders, these molecules are major signs of inflammation. In mice exposed to unpredictable chronic mild stress (UCMS) challenged, the study disclosed significant inhibition of these proinflammatory cytokines by administration of ARE; these molecules are compulsory for the starting and maintaining brain inflammation. ARE preserves neuronal wellbeing by preventing these inflammatory molecules and therefore keeping under control the harmful effects of chronic stress and inflammation. The ability of ARE to reduce inflammation shows that it might be a natural medicinal molecule used in the management of depression and other mood disorders related to stress induced neuroinflammation ^{14,52,53,54,55}. Likewise, Curcuma longa (turmeric) extract has significant anti-inflammatory action by acting on several inflammatory pathways, including the nuclear factor-kappa B (NF-κB) signaling pathway, which is an important regulator of immune responses and inflammation. The active ingredient in Curcuma longa, curcumin, has been reported to suppress the expression of pro-inflammatory cytokines like TNF-α, IL-6, and IL-1β, which are increased in many inflammatory and neurodegenerative diseases. Through the inhibition of COX2 and iNOS, curcumin successfully suppresses the synthesis of inflammatory mediators’ prostaglandins and nitric oxide, respectively, and thereby inhibits chronic inflammation and tissue damage. In experimental chronic stress models, curcumin supplementation noticeably reduced the levels of inflammatory cytokines, much the same as was seen with Ashwagandha. Curcumin also promote neuroprotection through the induction of antioxidant defense mechanisms, which helps to further diminish inflammation-induced neuronal injury ^14,56,57.

2.4. Controlling of the Hypothalamic-Pituitary-Adrenal (HPA) Axis: Expanded cortisol level and chronic stress arise with anxiety and depression ¹⁵. According to research adaptogenic herbs such as Ashwagandha and Panax ginseng aid in controlling the HPA axis, thereby diminishing cortisol production and enhancing stress perseverance ¹⁶.

2.4.1. Role of the HPA Axis in Response to Stress: The HPA axis is an advanced neuroendocrine system that governs the body's response to stress. Hypersecretion of cortisol is a consequence of continuous HPA axis stimulation due to chronic stress. Depression and anxiousness have been associated with these dysfunctions ^{15,58,59,60,61}.

<a href="https://www.ijpsjournal.com/uploads/createUrl/createUrl-20250601193812-1.png" target="_blank">
<img alt="6.png" height="150" src="https://www.ijpsjournal.com/uploads/createUrl/createUrl-20250601193812-1.png" width="150">
</a>
Figure 6: Working of Hypothalamic-Pituitary-Adrenal (HPA) Axis

3. Important Herbal Extracts Assessed in Study:

3.1. Erythrina sp. Extract: Preclinical studies show that extracts of Erythrina sp. have significant anxiolytic and antidepressant effects, mainly through modulation of the GABAergic system ¹⁷. In animal studies, reduced anxiety behavior with treatment using Erythrina extracts has been shown, indicating its use as a natural anxiolytic drug ^18,62,63,64.

3.2. Clitoria ternatea (Butterfly Pea) Extract: Clitoria ternatea has a long history in Ayurvedic medicine for its perceived effects on cognitive function and mental well-being ¹⁹. Early research indicates that it raises levels of serotonin and dopamine, thereby justifying its effect like antidepressants ^20,65,66.

3.3. Essential Oils in Aromatherapy: Scientific investigations have demonstrated that essential oils including lavender ^67,68,69 and bergamot ^70,71 and sandalwood can reduce feelings of anxiety according to studies on aromatherapy. The essential oils make contact with the limbic system while controlling neurotransmitters and behavioral responses to stress ²¹.

3.4. Chinese Herbal Extract (CHE): The nervous system depends on essential neurotransmitters such as serotonin (5-HT) and GABA to control mood because CHE influences these biological elements or neurotransmitters. Schisandra (Wuweizi)⁸⁰ along with Astragalus (Huangqi) serve as specific herbs that work to control or maintain emotional reactions. CHE medications frequently show their ability to reduce cortisol levels so the human body can efficiently handle stress. Herbal medications restructure the hypothalamic-pituitary-adrenal (HPA) regulatory system to decrease stress-related reactions. CHE proves effective for treating insomnia since insomnia frequently develops as a result of anxiety. The sleep pattern improvements of Shumian Capsule proved powerful enough to minimize stress alongside reducing anxiety symptoms. The bioactive elements found in CHE act to decrease oxidative stress and reduce inflammation therefore helping with mental wellness ^4,72.

3.5. St. John's Wort (Hypericum perforatum): Studies have demonstrated that St. John's Wort (Hypericum perforatum) is just as effective as SSRIs in treating mild to moderate depression, with fewer adverse effects. In addition to modulating inflammatory cytokines, it exhibits activity via blocking the reuptake of serotonin (5-HT), dopamine (DA), and norepinephrine (NE) ^{35, 43}.

3.6. Valerian Root (Valeriana officinalis): Patients suffering from generalized anxiety disorder (GAD) report fewer symptoms of stress and worry. It modifies serotonin receptors, raises GABA availability, and improves the quality of sleep ^{37, 38}.

3.7. Lavender (Lavandula angustifolia): For patients with mild depression, lavender extract was reported to lower anxiety and elevate mood. Cortisol levels are lowered and GABA-A receptors are modulated. Additionally, it increases the activation of the 5-HT1A receptor, which is important for lowering anxiety ^{39, 40}.

3.8. Saffron (Crocus sativus): In Clinical trials saffron shows to be as effective as fluoxetine in treating major depressive disorder (MDD). It exhibits action through inhibiting serotonin reuptake, reduces oxidative stress, and regulates NMDA receptors ^36,41,42.

<a href="https://www.ijpsjournal.com/uploads/createUrl/createUrl-20250601193812-0.png" target="_blank">
<img alt="7.png" height="150" src="https://www.ijpsjournal.com/uploads/createUrl/createUrl-20250601193812-0.png" width="150">
</a>
Figure 7: Key Herbal Remedies for Anxiety and Depression

4. CONCLUSION: In summary, herbal plants are taken from natural source and their possible effectiveness and also their fewer serious side effects than traditional drugs, herbal extracts offer assured solutions for controlling anxiety and depression. By modulating neurotransmitter systems, decreasing oxidative stress and supporting neuroprotection, different kinds of plant-based ingredients including adaptogens, flavonoids, and alkaloids help their anxiolytic and antidepressant properties. Significant herbal extracts include St. John's Wort, Ashwaghanda, Valerian root and Passionflower have been shown to have key benefits in clinical and preclinical studies. Standardization, dosage consistency, and interactions with pharmaceutical medications all present still obstacles notwithstanding their medicinal value. Further meticulous scientific research is needed to determine the long-term consequences, effectiveness and safety. Combining traditional therapies with herbal medicine could give a total approach to psychological health that stresses the need of proper use to be under medical expert control. Research and regulatory structures need to change to guarantee good quality & evidence based natural therapies as public interest in them rises. Future research should seek to find active ingredients, refine formulations and carry out significant clinical tests to confirm their effectiveness. Finally, provided under professional monitoring and based on research, herbal extracts offer a useful and complementary strategy in mental health care.

5. Challenges and Future Directions:

Although there are promising preclinical results, a number of issues need to be settled before herbal extracts can be universally recognized in clinical practice. One of the main issues is the absence of standardization in herbal preparations, which resulting in differences in active ingredient levels between products. Moreover, most herbal extracts have not been tested through large-scale human trials, and thus their acceptance in conventional medicine is restricted. The future studies should aim at performing randomized controlled trials (RCTs) and defining the exact molecular mechanisms behind the therapeutic actions of herbal extracts.

Standardization and Quality Control: The lack of standardization in harvesting, extraction, and processing of plant extracts. It only impacts reproducibility and therapeutic performance when bioactive compounds are reproducible, and that is based on harvesting methods, soil, and climate conditions. High-performance liquid chromatography (HPLC) and mass spectrometry would be welcome additions to enhance the quality control standards.
Mechanistic Understanding and Target Specificity: Although herbal extracts exhibit antidepressant and neuroprotective activity, the molecular targets for the action of such extracts are currently unknown. Most bioactive compounds from plants work through multiple targets, such as the inhibition of oxidative stress, modulation of the levels of neurotransmitters, and inflammatory responses. The precise mechanism by which the flavonoid component of plant sources, such as fisetin, provides neuroprotection and anti-oxidative protection from damage and inflammation in depression and anxiety disorders needs to be clarified.

Pharmacokinetics and Bioavailability: Poor bioavailability of phytochemicals derived from plant sources is one of the significant barriers to clinical translation. As therapeutic agents, most of the active phytochemicals are weaker in action due to their poor solubility & poor oral bioavailability following gut absorption, and extensive metabolism. Lipid carrier-based delivery and nanoencapsulation are two new drug delivery systems that have the potential to increase drug delivery and bioavailability to the central nervous system (CNS).

REFERENCES

Risdiana, N., Aulawi, K., & Sholikhah, E. N. (2025). Preclinical studies of anti-anxiety and anti-depressant-like effects of Erythrina sp. plant extract: Systematic review and meta-analysis. Journal of Pharmacognosy and Research, 13(4), 1045–1058.
SR, S. K., Sherief, S. H., Tawale, H., Balasaheb, A., Borse, G. N., & Gupta10, V. L. A COMPREHENSIVE EVALUATION OF CLITORIA TERNATEA ITS BOTANICAL DESCRIPTION, PHYTOCHEMISTRY, PHARMACOLOGICAL ACTIVITIES, AND TRADITIONAL USES.
Babar, G., Kazi, S., & Bais, S. K. (2025). Indian medicinal plant used in aromatherapy. International Journal of Pharmacy and Herbal Technology, 3(1), 3270–3282.
Tsang, M. S., Zhou, I. W., Zhang, A. L., & Xue, C. C. (2025). Chinese herbal medicine for dyspnea and persistent symptoms of long COVID: A systematic review and meta-analysis of randomized controlled trials. Journal of Integrative Medicine.
Wang, G., Ding, T., & Ai, L. (2024). Effects and mechanisms of probiotics, prebiotics, synbiotics, and postbiotics on intestinal health and disease. Frontiers in Cellular and Infection Microbiology, 14, 1430312.
Bailly, C. (2025). A systematic review of proaporphine alkaloids and a pharmacological update. Phytomedicine Plus, 5, 100689.
Kumari, B., & Dixit, A. K. (2025). Efficacy of formulations for treating hyperpigmentation: A systematic review and meta-analysis. Archives of Dermatological Research, 317(1), 379.
Frost, R., Mathew, S., Thomas, V., Uddin, S., Salame, A., Vial, C., et al. (2024). A scoping review of over-the-counter products for depression, anxiety and insomnia in older people. BMC Complementary Medicine and Therapies, 24, 275.
Banerjee, S., Saha, D., Sharma, R., Jayadee, W., Puttarak, P., Chaiyakunapruk, N., & Chaoroensup, R. (2024). Phytocannabinoids in neuromodulation: From omics to epigenetics. Journal of Ethnopharmacology.
Booker, A., Zabetakis, I., Teusch, N. E., Dalby, A., Hartung, T., & Peter, A. E. (2025). Multisystem inflammatory syndrome observed post-COVID-19: The role of natural products, medicinal plants and nutrients and the use of prediction tools supporting traditional forms of diagnosis. Frontiers in Pharmacology, 16, 1539793.
Wang, G., Ding, T., & Ai, L. (2024). Effects and mechanisms of probiotics, prebiotics, synbiotics and postbiotics on intestinal health and disease. Frontiers in Cellular and Infection Microbiology, 14, 1430312.
Chattopadhyay, S., & Malayil, L. (2024). Reviews in microbiome in health & disease. Frontiers in Cellular and Infection Microbiology, 14, 1423386.
Kim, H., Choi, H. S., Han, K., Sim, W., Suh, H. J., & Ahn, Y. (2025). Withania somnifera root extract containing withanolide A alleviates depression-like behavior in mice by enhancing the BDNF pathway under UCMS. Journal of Ethnopharmacology, 340, 119224.
Oliveira Junior, P. C., Sanjinez-Argandoña, E. J., Faoro, J. A. M., Silva, R. M. M. F., Konkiewitz, E. C., Ziff, E. B., et al. (2024). Guettarda viburnoides: Neuroprotective activities in mice, molecular docking, and anatomical characteristics. Current Pharmaceutical Biotechnology.
Yeo, S. H., Herde, M. K., & Herbison, A. E. (2021). Morphological assessment of GABA and glutamate inputs to GnRH neurons using expansion microscopy. Journal of Neuroendocrinology, 33(9), e13021.
Marmitt, D. J., Bitencourt, S., do Couto e Silva, A., Rempel, C., & Goettert, M. I. (2018). Medicinal plants with neuroprotective potential in Brazil’s public health system: A systematic review. Boletin Latinoamericano y del Caribe de Plantas Medicinales y Aromaticas, 17(2).
Rahman, M. R., Ali, M., Sharif, M., & Tajmim, A. J. (2017). A review of traditional plants with antidepressant properties. MOJ Cell Science Report, 4(5), 138–145.
Pannu, A., Sharma, P. C., Thakur, V. K., & Goyal, R. K. (2021). Emerging role of flavonoids in the treatment of depression. Biomolecules, 11(11), 1825.
Ghidersa, M., Negru, A. M., Plavan, G., Ciobica, A., & Rashwan, E. H. (2025). Meta-analysis on plant extracts’ neuropsychiatric benefits studied in zebrafish models.
Mhaiskar, A., Bagul, V., & Patil, S. (2025). Neuroprotective properties of medicinal plants: A comprehensive review.
Falconi-Souto, A., Morales-Lima, G., Kuroki, Y., & Mendes, F. R. (2025). Psychopharmacology of Brazilian native plants focusing on mood: A systematic review. Current Research in Complementary and Alternative Medicine, 9(262), 2577–2601.
Jensen, M. G., Goode, M., & Heinrich, M. (2024). Herbal medicines for insomnia, stress, anxiety, and depression: Evidence review with a focus on the Middle East and Africa. PharmaNutrition, 100399.
Zhang, N., Zhang, S., & Dong, X. (2024). Plant-derived compounds in CNS disorder treatment via ATF4 targeting: A review. Biomedicine & Pharmacotherapy, 176, 116811.
Hassan, S. S., Samanta, S., Dash, R., Karpi?ski, T. M., Habibi, E., Sadiq, A., et al. (2022). Neuroprotective effects of fisetin in neurodegenerative diseases: Role of oxidative stress. Frontiers in Pharmacology, 13, 1015835.
Jiang, Y., Zou, D., Li, Y., Gu, S., Dong, J., Ma, X., et al. (2022). Monoamine neurotransmitters and their role in major depressive disorder. Pharmaceuticals, 15(10), 1203.
Ye, H., Ji, M., Wang, C., et al. (2022). Functional neuroimaging and neurotransmitter analysis in ICU staff with depressive tendency due to sleep deprivation. Frontiers in Psychiatry, 13, 848709.
Gu, S., Wang, F., Cao, C., Wu, E., Tang, Y. Y., & Huang, J. H. (2019). Studying emotions with fMRI: An integrative approach. Frontiers in Neuroscience, 13, 628.
Markers, D. (2023). [Retracted] Neurotransmitters and electrophysiological changes as biomarkers for affective disorders. Disease Markers, 2023, 9792838.
Wang, F., Pan, F., Tang, Y. Y., & Huang, J. H. (2022). Emotional disorders from uncertainty during COVID-19. Frontiers in Psychology, 13, 943966.
Jewett, B. E., & Sharma, S. (2023). Physiology, GABA. In StatPearls. StatPearls Publishing.
Möhler, H. (2012). The GABA system in anxiety and depression and its therapeutic potential. Neuropharmacology, 62(1), 42–53.
Felice, D., Cryan, J. F., & O’Leary, O. F. (2020). GABAB receptors: Anxiety and mood disorders. In Behavioral Neurobiology of GABAB Receptor Function (pp. 241–265). Springer.
Nuss, P. (2015). Anxiety disorders and GABA neurotransmission: A disturbance of modulation. Neuropsychiatric Disease and Treatment, 11, 165–175.
Arora, I., Mal, P., Arora, P., Paul, A., & Kumar, M. (2024). GABAergic implications in anxiety and related disorders. Biochemical and Biophysical Research Communications, 150218.
Wang, X., Sun, M., Wang, L., Li, J., Xie, Z., Guo, R., Wang, Y., & Li, B. (2023). Dietary inflammatory index and physical activity in depressive symptoms: NHANES 2007–2016. Journal of Affective Disorders, 335, 332–339.
Fang, M., Fan, Z., Liu, S., Feng, S., Zhu, H., Yin, D., Jia, H., & Wang, G. (2023). Preventive interventions for those at risk of bipolar disorder: A systematic review. Journal of Affective Disorders, 340, 53–63.
Murphy, K., Kubin, Z. J., Shepherd, J. N., & Ettinger, R. (2010). Valeriana officinalis root extracts have potent anxiolytic effects in rats. Phytomedicine, 17(8–9), 674–678.
Jung, H. Y., Yoo, D. Y., Kim, W., Nam, S. M., Kim, J. W., Choi, J. H., et al. (2014). Valeriana officinalis root extract suppresses stress responses in rats. BMC Complementary and Alternative Medicine, 14, 1–8.
Firoozeei, T. S., Feizi, A., Rezaeizadeh, H., Zargaran, A., Roohafza, H. R., & Karimi, M. (2021). Antidepressant effects of lavender: Systematic review and meta-analysis. Complementary Therapies in Medicine, 59, 102679.
Kim, M., Nam, E. S., Lee, Y., & Kang, H. J. (2021). Effects of lavender on anxiety and depression: Systematic review and meta-analysis. Asian Nursing Research, 15(5), 279–290.
Mazidi, M., Shemshian, M., Mousavi, S. H., Norouzy, A., Kermani, T., Moghiman, T., et al. (2016). Crocus sativus (Saffron) in anxiety and depression: A double-blind trial. Journal of Complementary and Integrative Medicine, 13(2), 195–199.
Kumar, V., Kaur, N., & Wadhwa, P. (2022). Clinical evidence on the effects of Crocus sativus in anxiety and depression. World Journal of Traditional Chinese Medicine, 8(2), 181–187.
Bukhari, I. A., & Dar, A. (2013). Behavioral profile of Hypericum perforatum (St. John’s Wort): Comparison with antidepressants. European Review for Medical and Pharmacological Sciences, 17(8).
Rashmi, D., Zanan, R., John, S., Khandagale, K., & Nadaf, A. (2018). GABA: Biosynthesis, role, production, and applications. In Studies in Natural Products Chemistry (Vol. 57, pp. 413–452).
Enna, S. J. (2007). The GABA receptors. Humana Press.
Martin, I. L., & Dunn, S. M. (2002). GABA receptors. Tocris Reviews, 20(1), 1–8.
Sarawagi, A., Soni, N. D., & Patel, A. B. (2021). Glutamate and GABA homeostasis in major depressive disorder. Frontiers in Psychiatry, 12, 637863.
Kalueff, A. V., & Nutt, D. J. (2007). Role of GABA in anxiety and depression. Depression and Anxiety, 24(7), 495–516.
Charney, D. S. (2003). Neuroanatomical circuits modulating fear and anxiety behaviors. Acta Psychiatrica Scandinavica, 108(Suppl. 417), 38–50.
Cortese, B. M., & Phan, K. L. (2005). The role of glutamate in anxiety disorders. CNS Spectrums, 10(10), 820–830.
Khoodoruth, M. A., Estudillo-Guerra, M. A., Pacheco-Barrios, K., Nyundo, A., Chapa-Koloffon, G., & Ouanes, S. (2022). Glutamatergic system in depression and neuromodulatory techniques. Frontiers in Psychiatry, 13, 886918.
Speers, A. B., Cabey, K. A., Soumyanath, A., & Wright, K. M. (2021). Effects of Withania somnifera (Ashwagandha) on stress and the stress-related neuropsychiatric disorders anxiety, depression, and insomnia. Current neuropharmacology, 19(9), 1468-1495.
Lopresti, A. L., Smith, S. J., Malvi, H., & Kodgule, R. (2019). An investigation into the stress-relieving and pharmacological actions of an ashwagandha (Withania somnifera) extract: A randomized, double-blind, placebo-controlled study. Medicine, 98(37), e17186.
Gannon, J. M., Brar, J., Rai, A., & Chengappa, K. R. (2019). Effects of a standardized extract of Withania somnifera (Ashwagandha) on depression and anxiety symptoms in persons with schizophrenia participating in a randomized, placebo-controlled clinical trial. Annals of Clinical Psychiatry, 31(2), 123-129.
Güllü, H., & K?ro?lu, O. (2024). Clinical applications of Ashwagandha plant in depression and anxiety. Cukurova Medical Journal, 49(3), 818-833.
Ramaholimihaso, T., Bouazzaoui, F., & Kaladjian, A. (2020). Curcumin in depression: potential mechanisms of action and current evidence—a narrative review. Frontiers in psychiatry, 11, 572533.
Lopresti, A. L. (2022). Potential role of curcumin for the treatment of major depressive disorder. CNS drugs, 36(2), 123-141.
Adinoff, B., Junghanns, K., Kiefer, F., & Krishnan?Sarin, S. (2005). Suppression of the HPA axis stress?response: implications for relapse. Alcoholism: Clinical and Experimental Research, 29(7), 1351-1355.
Chrousos, G. P. (2000). The HPA axis and the stress response. Endocrine research, 26(4), 513-514.
Guilliams, T. G., & Edwards, L. (2010). Chronic stress and the HPA axis. The standard, 9(2), 1-12.
Smith, S. M., & Vale, W. W. (2006). The role of the hypothalamic-pituitary-adrenal axis in neuroendocrine responses to stress. Dialogues in clinical neuroscience, 8(4), 383-395.
Ribeiro, M. D., Onusic, G. M., Poltronieri, S. C., & Viana, M. B. (2006). Effect of Erythrina velutina and Erythrina mulungu in rats submitted to animal models of anxiety and depression. Brazilian journal of medical and biological research, 39, 263-270.
Chu, H. B., Tan, Y. D., Li, Y. J., Cheng, B. B., Rao, B. Q., & Zhou, L. S. (2019). Anxiolytic and anti-depressant effects of hydroalcoholic extract from Erythrina variegata and its possible mechanism of action. African Health Sciences, 19(3), 2526-2536.
Martins, J., & Brijesh, S. (2020). Anti-depressant activity of Erythrina variegata bark extract and regulation of monoamine oxidase activities in mice. Journal of ethnopharmacology, 248, 112280.
Mittal, S., Gupta, P., & Nigam, V. (2021). Evaluation of antidepressant-like effect of Clitoria ternatea Linn. Research Journal of Pharmacy and Technology, 14(12), 6437-6441.
Rao, P., & Tanniru, R. (2023). Antianxiety studies on leaves of Clitoria ternatea Linn a high potential medicinal plant. Medicinal Plant, 7(2), 000253.
Bagheri-Nesami, M., Shorofi, S. A., Nikkhah, A., & Espahbodi, F. (2017). The effects of lavender essential oil aromatherapy on anxiety and depression in haemodialysis patients. Pharmaceutical and Biomedical Research, 3(1), 8-13.
Jafari-Koulaee, A., Elyasi, F., Taraghi, Z., Ilali, E. S., & Moosazadeh, M. (2020). A systematic review of the effects of aromatherapy with lavender essential oil on depression. Central Asian journal of global health, 9(1), e442.
Malcolm, B. J., & Tallian, K. (2017). Essential oil of lavender in anxiety disorders: Ready for prime time?. Mental Health Clinician, 7(4), 147-155.
Han, X., Gibson, J., Eggett, D. L., & Parker, T. L. (2017). Bergamot (Citrus bergamia) essential oil inhalation improves positive feelings in the waiting room of a mental health treatment center: A pilot study. Phytotherapy research, 31(5), 812-816.
Rombolà, L., Tridico, L., Scuteri, D., Sakurada, T., Sakurada, S., Mizoguchi, H., ... & Morrone, L. A. (2017). Bergamot essential oil attenuates anxiety-like behaviour in rats. Molecules, 22(4), 614.
Li, C., Huang, J., Cheng, Y. C., & Zhang, Y. W. (2020). Traditional Chinese medicine in depression treatment: from molecules to systems. Frontiers in pharmacology, 11, 586.
Mittal, S., Gupta, P., & Nigam, V. (2021). Evaluation of antidepressant-like effect of Clitoria ternatea Linn. Research Journal of Pharmacy and Technology, 14(12), 6437-6441.
Bandelow, B., Michaelis, S., & Wedekind, D. (2017). Treatment of anxiety disorders. Dialogues in clinical neuroscience, 19(2), 93-107.
Papp, L. A. (2007). Pharmacological approach to the management of stress and anxiety disorders. Principles and practice of stress management, 579-612.
Mizoguchi, K., & Ikarashi, Y. (2017). Multiple psychopharmacological effects of the traditional Japanese Kampo medicine Yokukansan, and the brain regions it affects. Frontiers in Pharmacology, 8, 149.
Toriizuka, K., Kamiki, H., Ohmura, N. Y., Fujii, M., Hori, Y., Fukumura, M., ... & Ida, Y. (2005). Anxiolytic effect of Gardeniae Fructus-extract containing active ingredient from Kamishoyosan (KSS), a Japanese traditional Kampo medicine. Life sciences, 77(24), 3010-3020.
López, V., Cásedas, G., Petersen-Ross, K., Powrie, Y., & Smith, C. (2022). Neuroprotective and anxiolytic potential of green rooibos (Aspalathus linearis) polyphenolic extract. Food & Function, 13(1), 91-101.
Fedotova, J., Kubatka, P., Büsselberg, D., Shleikin, A. G., Caprnda, M., Dragasek, J., ... & Kruzliak, P. (2017). Therapeutical strategies for anxiety and anxiety-like disorders using plant-derived natural compounds and plant extracts. Biomedicine & Pharmacotherapy, 95, 437-446.
Liu, J., Shi, J. L., Guo, J. Y., Chen, Y., Ma, X. J., Wang, S. N., ... & He, S. (2023). Anxiolytic-like effect of Suanzaoren–Wuweizi herb-pair and evidence for the involvement of the monoaminergic system in mice based on network pharmacology. BMC Complementary Medicine and Therapies, 23(1), 7.